FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 357:1357 September 27, 2007 Number 13 Next

PDF PDA Full Text Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Schreiber, S.

Maintenance Therapy with Certolizumab Pegol for Crohn's Disease . The second sentence of the first paragraph (page 240) should have read "Infliximab and adalimumab are engineered IgG1 monoclonal antibodies that bind to TNF- (the first represents a chimeric molecule and the latter has been derived from human origin) and are effective in the induction and maintenance of response and remission in patients with Crohn's disease," rather than "Infliximab and adalimumab are IgG1 chimeric monoclonal antibodies that bind to TNF- and are effective in the induction and maintenance of response and remission in patients with Crohn's disease." Also, the last sentence in the legend for Figure 2 (page 244) should have read "The median score was significantly lower in the certolizumab group than in the placebo group at week 16 (P=0.03), week 20 (P=0.02), week 24 (P=0.008), and week 26 (P<0.001)" rather than "The median score was significantly higher." The text has been corrected on the Journal's Web site at www.nejm.org. We regret the errors.

PDF PDA Full Text Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Schreiber, S.

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.